Polycystic kidney disease is a lifelong condition. It begins with cyst formation in the kidneys, progresses over decades as cysts grow and multiply, and in the majority of patients with the most common form (ADPKD) leads to kidney failure requiring renal replacement therapy by the fifth or sixth decade of life. The management of PKD has transformed over the past decade. The 2025 KDIGO Clinical Practice Guideline on ADPKD provides the most comprehensive evidence-based framework yet for disease-modifying treatment, surveillance, and kidney transplant planning.
For international patients from Nigeria, Bangladesh, Kenya, the UAE, and South Asia who are navigating this diagnosis, India offers the full PKD management spectrum from tolvaptan therapy and blood pressure optimisation through dialysis and kidney transplant at world-standard quality and 60 to 80 percent lower cost than Western equivalents.
Understanding Polycystic Kidney Disease: Types and Progression
PKD is not a single condition. Two distinct genetic disorders share the name, and their management differs significantly.
ADPKD: The Most Common Form
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 or PKD2 genes, producing cyst formation throughout the kidney parenchyma. It is the most common monogenic kidney disease, affecting approximately one in 1,000 people. ADPKD is inherited in an autosomal dominant pattern, meaning each child of an affected parent has a 50 percent probability of inheriting the condition.
Progression varies considerably: PKD1 mutations produce faster progression than PKD2 mutations. Kidney failure typically occurs between 55 and 65 years in PKD1-mutant disease and between 65 and 75 years in PKD2-mutant disease. Hypertension develops early, often in the second or third decade, before kidney function begins to decline. Intracranial aneurysms occur in approximately 8 to 12 percent of ADPKD patients, a risk significantly higher than the general population.
Tolvaptan, a selective vasopressin V2 receptor (V2R) antagonist, is the first and only approved disease-modifying therapy for ADPKD. Its approval based on the landmark TEMPO 3:4 trial marked a transformation in ADPKD management from general CKD measures to targeting disease-specific mechanisms.
The TEMPO 3:4 trial randomised 1,445 ADPKD patients with TKV of at least 750 mL and creatinine clearance at or above 60 mL/min to tolvaptan or placebo for three years. Tolvaptan significantly reduced the annual rate of TKV increase and significantly slowed eGFR decline compared to placebo. The REPRISE trial subsequently confirmed tolvaptan's efficacy in patients with later-stage ADPKD (eGFR 25 to 65 mL/min per 1.73 m²), extending its evidence base to patients with more advanced disease.
The 2025 KDIGO CPG on ADPKD provides updated guidance on tolvaptan patient selection, dosing titration, monitoring for hepatotoxicity (elevated liver enzymes in approximately 5 percent of patients, reversible on discontinuation), and management of aquaretic side effects (thirst and frequent urination, which affect most patients and lead to discontinuation in some).
A September 2025 Current Opinion in Nephrology and Hypertension review confirms that while tolvaptan remains the only FDA-approved therapy targeting disease progression, a growing pipeline of novel therapies including mTOR inhibitors, CFTR modulators, CDK inhibitors, and metabolic reprogramming approaches are in preclinical and early clinical stages.
In India, tolvaptan is available at significantly lower cost than in the USA or UK. Branded tolvaptan (Samsca) and generic formulations are accessible at leading nephrology centres, with the annual drug cost representing substantial savings that make long-term tolvaptan therapy financially achievable for international patients.
Managing ADPKD Complications
Beyond blood pressure and tolvaptan, ADPKD management addresses specific complications that arise through the disease course:
-
Cyst infections: Treated with antibiotics that penetrate cyst fluid fluoroquinolones (ciprofloxacin, levofloxacin) are the agents of choice because of their lipid-soluble cyst penetration.
-
Cyst haemorrhage: Usually self-limiting and managed conservatively with rest, hydration, and analgesia. Rarely requires intervention.
-
Nephrolithiasis: Kidney stones occur at higher rates in ADPKD than in the general population. Management includes high fluid intake, dietary modification, and targeted pharmacological treatment depending on stone composition.
-
Intracranial aneurysm screening: Screening with MRA is recommended for patients with a the degree of kidney enlargement, symptom burden, and the surgical approach preferred by the transplant team.
Pre-emptive Transplant for PKD
Pre-emptive transplant performing the kidney transplant before dialysis is needed, when eGFR falls to approximately 10 to 15 mL/min is the optimal strategy when a living donor is available. Pre-emptive transplant eliminates the physiological burden of dialysis, reduces cardiovascular risk, and produces the best long-term graft and patient survival outcomes.
For PKD patients with a family member willing to donate, genetic testing of the potential donor is important to confirm that the donor does not carry the same PKD mutation. A living related donor with ADPKD themselves is not an appropriate kidney donor.
Kidney Transplant in India for PKD Patients
For the full framework on kidney transplant access in India including the SAC committee process for living donors, THOTA legal compliance, and hospital selection criteria, read: How to Choose the Right Hospital for End-Stage Renal Disease Treatment in India
Living donor kidney transplant for PKD patients in India costs Rs. 8,00,000 to Rs. 15,00,000 (USD 9,600 to USD 18,000), representing savings of 85 to 92 percent versus the USA.
Cost of PKD Treatment in India for International Patients
| Treatment | India cost | USA / UK equivalent |
|---|---|---|
| Nephrology consultation and PKD assessment | Rs. 1,500 to Rs. 3,000 (USD 18 to USD 36) | USD 300 to USD 600 |
| MRI for htTKV (Mayo class staging) | Rs. 8,000 to Rs. 15,000 (USD 96 to USD 180) | USD 1,500 to USD 3,000 |
| Tolvaptan (per month, generic) | Rs. 5,000 to Rs. 15,000 (USD 60 to USD 180) | USD 6,000 to USD 12,000 |
| Haemodialysis (per session) | Rs. 800 to Rs. 2,500 (USD 10 to USD 30) | USD 300 to USD 500 |
| Living donor kidney transplant | Rs. 8,00,000 to Rs. 15,00,000 (USD 9,600 to USD 18,000) | USD 100,000 to USD 300,000 |
| Post-transplant immunosuppression (per year) | Rs. 80,000 to Rs. 2,00,000 (USD 960 to USD 2,400) | USD 10,000 to USD 30,000 |
The tolvaptan cost difference is particularly significant: USD 60 to USD 180 per month in India versus USD 6,000 to USD 12,000 per month in the USA makes disease-modifying therapy
6,000 to USD 12,000 in the USA), high fluid intake and dietary modification, management of complications including cyst infection and intracranial aneurysms, and kidney transplant when ESRD is reached.
How Karetrip Connects International PKD Patients to India's Nephrology Centres
Managing ADPKD requires a nephrologist who understands the 2025 KDIGO guideline framework, can stratify disease progression by MRI-based TKV, initiate and monitor tolvaptan safely, and coordinate the transition to kidney transplant when ESRD approaches. Karetrip reviews each patient's existing renal function data, blood pressure records, and imaging before recommending a nephrology centre in India, confirming the proposed team has specific PKD management experience.
For patients approaching ESRD, Karetrip coordinates the transplant evaluation alongside the nephrology management, ensuring the transition from pre-ESRD care to transplant listing and surgery is managed as a single coordinated pathway.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward expert PKD management and transplant planning at India's leading nephrology centres.